Brickell Biotech to Report First Quarter 2020 Financial Results on May 13, 2020
May 04, 2020 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., May 04, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 18, 2020 16:01 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., March 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech to Report Fourth Quarter and Full Year 2019 Financial Results on March 18, 2020
March 09, 2020 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., March 09, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting by its Asian Partner, Kaken Pharmaceutical, for Sofpironium Bromide
March 04, 2020 06:30 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., March 04, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology
February 20, 2020 06:30 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Announces Settlement of Dispute with Bodor Labs and Entry into Equity Funding Agreements
February 18, 2020 06:30 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing...
Brickell Bio’s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis
January 10, 2020 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update
November 13, 2019 16:05 ET
|
Brickell Biotech, Inc.
BOULDER, Colo., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
October 30, 2019 16:42 ET
|
Brickell Biotech, Inc.
NovaQuest temporarily suspended R&D funding payments Brickell filed a motion to dismiss the complaint filed by Bodor Labs and Nicholas S. Bodor in federal court Brickell initiated arbitration...
Brickell Biotech Completes Merger with Vical
September 03, 2019 06:45 ET
|
Brickell Biotech
Newly Nasdaq-listed BBI focused on developing differentiated therapeutics for treatment of dermatologic disorders Merger brings $60 Million in Combined Cash from Vical and R&D funding from...